Characteristics of patients with response to nivolumab

AgePSGenomic alterationPD-L1+ in TCCPS≥10CPS≥1EBVMMR
MutationAmplificationTMB/Mb
630NENENE++MMR-D
630NENENE+++MMR-D
660PIK3CA, TP53None38.3++MMR-D
620PIK3CANone11.5+MMR-D
531NoneNone7.7+++MMR-D
790MET, PIK3CA, TP53None58.0++MMR-D
640PIK3CANone15.3+++MMR-P
740ARID1A, TP53CCNE115.1+MMR-P
800TP53CCNE111.5+MMR-P
760NoneNone10.1+MMR-P
730TP53None5.0+++MMR-P
650NENENE+++MMR-P
530NENENE++MMR-P
430TP53None7.7++MMR-P

CPS combined positive score, EBV Epstein-Barr virus, MMR mismatch repair, MMR-D mismatch repair deficient, MMR-P mismatch repair proficient, NE not examined, ORR objective response rate, PD-L1 programmed cell death-1 ligand-1, PS Eastern Cooperative Oncology Group performance status, TMB tumor mutation burden